Royalty Report: Wound Care, Medical, Supply – Collection: 26656

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Wound Care
  • Medical
  • Supply
  • Therapeutic
  • Drugs
  • Pharmaceuticals
  • Pain
  • Nerve
  • Biotechnology
  • Surgical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26656

License Grant
A U.S. pharma has granted the worldwide rights to a U.S business unit of an Italian company the Knighton patent for all applications relating to the use of autologous platelet releasate therapies for healing purposes (wound-healing and tissue repair therapies).  U.S. Patent No. 5,165,938 entitled Wound Healing Agents.
License Property
5,165,938 A process for treating a wound of a live animal which comprises applying over the wound an effective amount of a treating composition containing the materials released by platelets during the platelet release reaction and facilitating healing of the wound.
Field of Use
Licensed Fields means any and all fields of use.

IPSCIO Record ID: 5492

License Grant
LICENSOR hereby grants to LICENSEE, to the extent of the LICENSED FIELD and LICENSED TERRITORY, a license under PATENTS, to fully practice PATENTS, including the right to make, use, offer for sale, sell and import PRODUCTS and promote the methods and compositions recited in the claims of PATENTS using PRODUCTS in the LICENSED FIELD.
License Property
The U.S. and foreign issued patents relates to platelet-based growth factors (used in platelet rich plasma gel used in wound care in the specific field of use covering diagnostic and therapeutic spinal, neurosurgery and orthopedic surgery. U.S. Patent No. 5,165,938 entitled “Wound Healing Agents,” issued 11/24/92.
Field of Use
SCHEDULE OF PRODUCTS
SEPARATORS
2760-40-101       Disposable Processing Kit – Single
2760-40-102       Disposable Processing Kit – Double

Disposable Processing Kits contain the items required for containing blood during processing in the centrifuge

CAPITAL
2760-40-000       Centrifuge
2760-40-310       Centrifuge and Cart Assembly

APPLICATORS/ MIXERS
2760-40-200       Applicator Kit

IPSCIO Record ID: 26542

License Grant
The Licensor granted the Licensee a non-exclusive License under the Licensed Patents to make, have made, use, import, sell, promote, market, offer for sale or otherwise transfer royalty-Bearing Products in the Licensed Fields throughout the world. This grant includes the right for the Licensee to grant subLicenses to this Agreement without payment of any additional royalty to the Licensor.
License Property
5,165,938 entitled 'Wound Healing Agents,' issued 11/24/92

Schedule of Disposable Products

Model Number Description UOM
7117-8200 Disposable Platelet Concentrator
(Market Evaluation Unit) One (1)
7117 8202  Disposable Platelet Concentrator One (1)
7117-8201 Graft Delivery System One (1)
7117-8203 Spray Applicator One (1)
7117-8204 Dual Lumen Applicator One (1)

Field of Use
“Licensed Fields” means all applications except use in treatment of diabetic foot ulcers, pressure ulcers, venous stasis and other wounds treated outside of surgery.

IPSCIO Record ID: 27075

License Grant
The Company has the exclusive right to utilize the process to make and apply AuTolo-Gel TM and full and exclusive right, title and interest, both national and international, to certain patent applications identified as the Patent Cooperation Treaty Application entitled Enriched Platelet Wound Healant the Licensor, an individual.
License Property
The AuTolo-Cure TM system is based upon the use of a process developed for the application of an autologous platelet-rich concentrated gel to chronic wounds. The process removes platelets from the individual, applies a process developed by Worden to create AuTolo-Gel TM and then applies the gel to the wound.  By using the patient’s own platelets to create the gel, the system is an autologous process.
Field of Use
The Company intends to market and sell its proprietary system for the treatment of chronic wounds presently identified by the servicemark, AuTolo-Cure TM ('the AuTolo-Cure TM system').   AuTolo(TM)-Gel is a proprietary autologous tissue coagulum for treating chronic nonhealing wounds such as; diabetic foot ulcers, venous stasis wounds and pressure ulcers.

IPSCIO Record ID: 26682

License Grant
Licensor hereby grants to Licensee for the a non-exclusive, royalty-bearing license to manufacture, have made, use, import, sell, promote, market, offer for sale, or otherwise transfer Platelet Products, Activated Platelet Gel Services and Experimental Platelet Gel Therapies for use in practicing or involving the practice of processes covered by one or more claims of the Licensed Patent in any field of use.
License Property
The controversy between the Parties based upon Licensee's manufacture, use, marketing, offer to sell, and/or sale of products alleged to infringe U.S. Patent No. 5,165,938.

Activated Platelet Gel Therapies are defined as methods of treating damaged tissues and/or wounds using topical compositions containing platelets activated by adding thrombin or another biologic release agent, or containing substances released from platelets after activation by adding thrombin or another biologic release agent.

Experimental Platelet Gel Therapies are defined as methods of treating damaged tissues and/or wounds using topical compositions containing platelets activated by locally present thrombin or another biologic release agent, or containing substances released from platelets after activation by locally present thrombin or another biologic release agent, i.e., without adding thrombin or another biologic release agent.

Schedule of SafeBlood Branded Single Use Disposable Kit Products
Item Description

Manufacturer Number

SafeBlood Graft Kit
                    
SBG KitSB101 / W

SafeBlood Graft Kit

SBG KitSB101 / W 1

SafeBlood Graft Kit

SBG KitSB102 / W

SafeBlood Graft Kit

SBG KitSB201 / W

SafeBlood Graft Kit

SBG Kit SB 103

SafeBlood Graft Kit 800-1001A(1)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(2)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(3)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(4)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(5)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(6)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(7)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A

BIOMETGPS 800-1001A

GPS Counter Balance

BIOMETGPS 800-0508

Schedule of SafeBlood Branded Single Use Disposable Component Products

Item Description

Manufacturer Number

SBG Graft Activator
    
CD SBG-1005

Ratio Procedure kit

Micromedics SA-4400

Blending Connector

Micromedics SA-3674

Single Spray Tip

Micromedics SA-3671

Dual Spray Applicator Tip

Micromedics SA-3660

Dual Tip

Micromedics SA-0205

Schedule of SafeBlood Branded Capital Equipment Products
Item Description

Manufacturer Number

GPS Centrifuge 120 Volt 50-60HZ
    
GPS – 7426

IPSCIO Record ID: 58867

License Grant
The Licensee entered into an exclusive license agreement with the Licensors for the use of their patent application for the method of producing autologous PRP to treat neuropathy.
License Property
The patent application is for a method of producing autologous PRP to treat neuropathy.  Neuropathy is a nerve disease causing numbness and pain.  Our products utilize Platelet rich plasma (PRP), a blood plasma derived product, which typically contains an elevated level of platelets and growth factors (at least four to eight times) than normal blood concentration. PRP appears to have beneficial effects for tendon, ligament or muscle injuries, maxillofacial therapies, dentistry, cosmetics, wound healing, cardiothoracic surgery, ear–nose–throat surgery, neurosurgery, urology, and ophthalmology.

Platelet-rich plasma (PRP) is blood plasma that has been enriched with platelets.

Field of Use
The Licensee will have exclusive rights to utilize this application in connection with the manufacture and sale of its neuropathy treatment products. The Licensee is currently developing products for treating peripheral neuropathy, hair loss and facial rejuvenation using platelet-rich plasma. As a concentrated source of autologous platelets, PRP contains (and releases through degranulation) several different growth factors and other cytokines that stimulate healing of bone and soft tissue, and can also be used as a treatment for hair regrowth. These products are not yet commercially available.

IPSCIO Record ID: 6865

License Grant
Licensor hereby grants to Licensees a non-exclusive license under the Licensed Patents to make, have made, use, import, sell, promote, market, or offer for sale Licensed Products in the Licensed Fields throughout the Licensed Territories.
License Property
U.S. Patent No. 5,165,938 entitled Wound Healing Agents, issued 11/24/92

On 6/3/2005 it has reached settlement agreement LicenseeTechnologies for infringing or seeking to avoid infringement of the Company’s patents. The underlying patents expired in late November 2009.

Field of Use
Licensed Fields means any and all fields of use.

The Company has established its intellectual property rights arising from its process patents regarding the use of platelet releasates to heal damaged tissue.

IPSCIO Record ID: 372627

License Grant
By the 2003 agreement, Licensor granted an exclusive worldwide sublicense for the Licensed Technology in the Field of Use and the Field of Extended Use.  This amended and restated agreement is to continue the Exclusive Sublicense with the amendments.

Licensor grants an exclusive worldwide license under the Licensed Technology to use, offer to sell, sell, and otherwise commercialize, solely in the Field of Use and the Field of Extended Use, Licensed Products which include rhPDGF-BB purchased from Licensor.

For the Sublicenses, Licensor grants the right to grant sublicenses under the Licensed Technology to Distributors to use, offer to sell and sell, in the Field of Use and the Field of Extended Use, Licensed Products purchased from Licensor.

License Property
Licensed Products means any product consisting essentially of rhPDGF-BB in the absence of other growth-promoting proteins and in combination with a synthetic or natural matrix, or any part thereof i.e., any product consisting essentially of rhPDGF-BB in the absence of other growth-promoting proteins without a matrix, or a synthetic or natural matrix alone, that is covered by the Licensed Patents; is developed through the use of a process that is covered by the Licensed Patents or could not be manufactured, used or sold without the incorporation or use in whole or in part of some or all of the Licensed Patents.

Proven rhPDGF technology is FDA approval of GEM 21S for periodontal bone regeneration suggests potential for efficacy in other bone and musculoskeletal applications.

Field of Use
GEM 21S was approved by the U.S. Food and Drug Administration the treatment of periodontal bone defects and gum tissue recession associated with periodontal disease.

GEM 21S® growth-factor enhanced matrix is indicated to treat the following periodontally related defects intrabony periodontal defects; furcation periodontal defects; and gingival recession associated with periodontal defects.

GEM 21S® growth-factor enhanced matrix combines a bioactive protein – highly purified rhPDGF-BB – with an osteoconductive matrix, ß-TCP.

GEM 21S® is the only dental therapy containing rhPDGF-BB, one of the main growth factors found in the human body and well known for its stimulatory role in wound healing.

This completely synthetic grafting system is engineered to stimulate wound healing and bone regeneration when implanted in the body by triggering a cascade of molecular events that continues on even after the implanted rhPDGF-BB is gone.

The Field of Use means all uses related to the treatment, cure, or relief of mammals for periodontal diseases and/or the repair, restoration or reconstruction of oral and cranio• maxillofacial osseous defects.

The Field of Extended Use shall mean all uses outside the Field of Use that are related to the treatment and healing of bone, cartilage, tendon and ligaments of the skeletal tissue system in animals, excluding humans, excluding the treatment and healing of soft tissue wounds.

IPSCIO Record ID: 26365

License Grant
The Licensee entered into an agreement with a national blood bank, under which the blood bank supplies the blood that serves as the raw material for, and manufactures, the Licensee's CureXcell product in Israel. Under the agreement, the blood bank produces CureXcell based on the Licensed Technology and based on the Licensee’s needs.
License Property
CureXcell is an injectable suspension of living human white blood cells, including macrophages, neutrophils and lymphocytes, that are crucial to initiating, promoting and completing the process of cellular regeneration and wound healing. The Licensee uses proprietary cell activation technology to trigger these cells to release growth factors and other biochemical factors that improve the healing environment in the wound bed and stimulate wound closure.
Field of Use
The CureXcell product is sold to health care professionals in Israel for clinical purposes as part of the Licensee’s research and development activities. The Licensee is a regenerative medicine company focused on developing, manufacturing and commercializing novel cell therapy products to address unmet needs in the treatment of chronic and other hard-to-heal wounds. Their product candidate, CureXcell, is an advanced wound care, or AWC, therapy to treat such wounds by injecting living human white blood cells that have been activated to facilitate the healing process. CureXcell is currently in two pivotal, Phase 3, double-blind clinical trials targeting a broad indication for the treatment of diabetic foot ulcers, or DFUs, and venous leg ulcers, or VLUs. The Licensee anticipates results from their DFU clinical trial and interim data from their VLU clinical trial in the second half of 2015. They already hold product approval for CureXcell as a medical device in Israel for the treatment of chronic and other hard-to-heal wounds, and have effectively and safely treated more than 5,000 patients in commercial or clinical study settings in Israel.

IPSCIO Record ID: 279344

License Grant
Licensor grants an exclusive option, for the duration of the Option Period, to acquire an exclusive right and license, with a right to grant and authorize sublicenses under the Patent Rights and Related Technology, to make, use and sell Licensed Products, to practice any process, method or procedure of the Patent Rights and Related Technology and to otherwise exploit the Patent Rights and the Related Technology.
License Property
The patents are for Compositions containing protease produced by vibrio and method of use in debridement and wound healing .
Field of Use
Licensee is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions.

IPSCIO Record ID: 7255

License Grant
We have acquired certain technology and other assets.

The technology and other assets acquired by us include the intellectual property rights related to development and production of Licensor's chronic wound treatment agent, Procuren(R), and all production equipment, leasehold improvements and certain other fixed assets.

License Property
Patents – the domestic and foreign patents being transferred from Licensor to Licensee pursuant to the Asset Purchase Agreement including any continuations-in-part, continuations, divisions, substitutes, reissues, reexaminations or extensions thereof.

Procuren – Procuren(R), a thrombin-induced platelet releasate.
Procuren is a wound-healing agent used to treat non-healing wounds

IPSCIO Record ID: 6876

License Grant
The Company is party to certain royalty agreements relating to its intellectual property under which it pays certain fees.
License Property
Company has established its intellectual property rights arising from its process patents regarding the use of platelet releasates to heal damaged tissue. Over several years it has reached settlement and/or licensing Agreements with numerous companies infringing or seeking to avoid infringement of the Company’s patents. The underlying patents expired in late November 2009. These dates reflect the expiration of the License in the U.S., which coincides with the expiration of the Knighton Patent in the U.S.

The Licensor's current patent portfolio consists of more than 30 domestic and international patents that generally fall into the following families

• Process, formulation, and methods for utilizing platelet releasates to heal damaged tissue  
• Biomarkers for wound healing treatment efficacy  
• Peptides with anti-inflammatory properties  
• Peptides with angiogenic properties

The above patent families encompass the Company’s AutoloGelTM System, CT-112 anti-inflammatory peptide, homologous growth factors, wound-healing biomarkers, and several other potential therapies.

Field of Use
The field of use relates to the medical industry.

IPSCIO Record ID: 27094

License Grant
The Licensee is to pay a royalty derived from the sale, license or other exploitation of the intellectual property of the Licensee to the Founder of the Company.  The Licensee, a development stage enterprise, is in the business of providing proprietary, turnkey solutions to the chronic wound care field through its AuTolo-Cure System developed by the Founder.
License Property
AuTolo(TM)-Gel is a proprietary autologous tissue coagulum for treating chronic non healing wounds such as; diabetic foot ulcers, venous stasis wounds and pressure ulcers.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 287764

License Grant
Under the terms of this agreement, the Company recognizes royalty revenue on sales of products containing the Companys patented resorbable bone hemostasis.
License Property
The Companys products are primarily purchased by hospitals and ambulatory surgical centers for use by surgeons on surgical wounds.
Field of Use
Licensed refers to certain bone wax rights to Licensee to develop products in the field of bone remodeling, based on Resorbable’s patent number 7,074,425 (see Note 9 “Intangible Assets”) for use in the human skeletal system.

The Company’s business is developing, marketing, and distributing wound and skin care products to physicians, hospitals, clinics and post-acute care settings.

IPSCIO Record ID: 227278

License Grant
University hereby grants to Licensee in the territory and in the field an exclusive commercial license under University patent rights, to make and have made, to use and have used, to sell and have sold the licensed products, and to practice the licensed processes, for the life of the university patent rights. Such licenses shall include the right to grant sublicenses.
License Property
Universitys rights in the United States Patents listed below, and the inventions described and claimed therein
U.S.P.N. 5,019,559 – Wound healing using PDGF and IGF-II
U.S.P.N. 4,861,757 – Wound healing and bone regeneration using PDGF and IGF-I
U .S.P.N. 5,124,316 – Method for periodontal regeneration
U.S.P.N. 4,874,746 – Wound healing composition of TGF-alpha and PDGF
U .S.P .N. 4,983,581 – Wound healing composition of IGF-I and TGF-.beta.
U.S.P.N. 5,256,644 – Wound healing using IGF-II and TGF
U.S.P,N. 5,034,375 – Process of wound healing using PDGF and EGF
U.S.P.N. 5,035,887 – Wound healing composition of IL-1 and PDGF or IGF-1
U.S.P.N. 5,516,699 – Pyridinoline crosslinks as markers of periodontal and peri-implant disease activity

rhPDGF is a bio-active protein that is a key mediator of wound healing and tissue regeneration.

Field of Use
rhPDGF is a key stimulator of the body's natural wound healing process. It has a well-established mechanism of action that leads to stimulation of certain cell types, including those important to bone, cartilage, tendon and ligament healing.

IPSCIO Record ID: 842

License Grant
The Licensor grants the Licensee an exclusive License to market the Product and an exclusive right to purchase from the Licensor and distribute the Product.
License Property
The Licensor has developed a proprietary wound dressing and has obtained United States Patent Nos. 7,351,430 and 7,910,135 in connection with the Product.

Patents shall mean United States Patent Nos. 7,351,430 and 7,910,135 in connection with the Product European Patent Application Nos. WO 2004/043438A1 and WO 2008/070270A2.; Australia Patent No. 10/289,756 and New Zealand Patent No. NZ540571(A).

Product means Altrazeal® medical device, in bulk or in finished form. All applications of Altrazeal® and the NanoFlex®

Technology in wound care including
Altrazeal® Base Product
Altrazeal® Silver
Altrazeal® Collagen

But excluding
Altrazeal® containing pharmaceutical actives subject to the drug approval process
Altrazeal® containing Biologics

ALTRAZEAL Transforming Powder Dressing is a revolutionary wound treatment technology that utilizes proprietary nanoflexâ„¢ technology to promote the healing of exuding wounds. ALTRAZEAL powder particles are the result of a rigorous development program where the product has been engineered to provide the necessary wound-healing benefits. ALTRAZEAL is designed to provide optimal oxygen and vapour transpiration, as well as microbial impermeability, tensile strength, and flexibility.

ALTRAZEAL consists of a sterile white powder in a single-use, sterile foil laminate pouch or transparent blister.

ALTRAZEAL is applied to an exuding wound by sprinkling the powder on to the open wound. The particles then hydrate and aggregate to a final moisture content of approximately 68% by mass. The aggregated powder becomes a moist, flexible dressing over the surface of the open wound that provides an ideal moist wound environment supporting cellular function and tissue repair.

Field of Use
Field means the human advanced wound management to include the treatment and control of both chronic and acute soft tissue injury.

IPSCIO Record ID: 3180

License Grant
In this agreement, the Licensor established a joint venture company with a German Company, the entity is the Licensee.

The Licensor has granted the Licensee global distribution rights in this regard.

This new enterprise is charged with obtaining the CE mark certification authorizing the distribution of the Hemospray wound spray in the member states of the European Union.

License Property
Hemospray Wound Spray

The Licensor has developed a novel medical product aimed at the healing of chronic wounds. Chronic wounds are a medical problem of increasing importance as they originate from widespread risk factors such as diabetes, obesity, smoking etc. Lack of oxygen supply to the cells in the wound ground is the main reason why those wounds lose their genuine healing power. Based on its concept of artificial oxygen carriers, our Hemospray wound spray product bridges the watery wound surface and permits an enhanced afflux of oxygen to the wound ground.

IPSCIO Record ID: 5299

License Grant
The Canadian Company grants the Licensee an exclusive license for the use and manufacture of the Thermal Bandage (United States Patent No. 5,431,622-July 11,1995) as well as other technology.
Field of Use
The rights granted apply to medical products.

IPSCIO Record ID: 28449

License Grant
Licensor hereby grants to Licensee a non-exclusive license under the Licensed Patents to make, have made, use, import, sell, promote, market, offer for sale or otherwise transfer Royalty-Bearing Products in the Licensed Fields throughout the world.
License Property
The Company established its intellectual property rights arising from its process patents regarding the use of platelet releasates to heal damaged tissue. Over several years it has reached settlement and/or licensing Agreements with numerous companies infringing or seeking to avoid infringement of the Company’s patents. These dates reflect the expiration of the License in the U.S., which coincides with the expiration of the Knighton Patent in the U.S.  The Licensee agreement was effective 10/28/06 through 11/24/2009; controversy between the parties arising in connection with claims of infringement of U.S. Patent No. 5,165,938.  

The Licensor's current patent portfolio consists of more than 30 domestic and international patents that generally fall into the following families
• Process, formulation, and methods for utilizing platelet releasates to heal damaged tissue  
• Biomarkers for wound healing treatment efficacy  
• Peptides with anti-inflammatory properties  
• Peptides with angiogenic properties

The above patent families encompass the Company’s AutoloGelTM System, CT-112 anti-inflammatory peptide, homologous growth factors, wound-healing biomarkers, and several other potential therapies.

Field of Use
Licensed Fields means any and all fields of use, worldwide.

IPSCIO Record ID: 27675

License Grant
The agreement licensed certain bone wax rights to develop products in the field of bone remodeling, based on patent number 7,074,425 for use in the human skeletal system.  The license agreement excludes the fields of (1) a resorbable hemostat (resorbable bone wax), (2) a resorbable orthopedic hemostat (bone wax) and antimicrobial dressing, and (3) veterinary orthopedic applications. In January 2014, Licensee received 510k approval for their first product under the license, a bioactive bone graft putty and bone graft extender.  In February 2014, Licensor granted a Commercial License to Licensee according to the terms of the development and license agreement.
License Property
The Licensor acquired patent 7,074,425 in September 2009.  It is for a resorbable bone wax and delivery system for orthopedic bone void fillers. The patent offers innovative, safe and effective resorbable orthopedic products that are complementary to the already existing Licensor products.  The bone wax and delivery system address issues such as bone wax granuloma and the cost-effective delivery of materials that manage bone wound healing. The resorbable orthopedic products covered by the patent are (a) a resorbable orthopedic hemostat (resorbable bone wax) used to stop blood flow, (b) a delivery system for osteogenic/osteoinductive orthopedic products (bone void fillers), and (c) the formula as a delivery system for bone growth factors.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.